Christopher Missling
Amministratore Delegato presso ANAVEX LIFE SCIENCES CORP.
Patrimonio netto: 5 M $ in data 30/06/2024
Posizioni attive di Christopher Missling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. | Direttore/Membro del Consiglio | - | - |
| Amministratore Delegato | 05/07/2013 | - | |
| Presidente | 05/07/2013 | - | |
| Segretario Aziendale | 05/07/2013 | - | |
| Presidente | - | - | |
| Direttore Finanziario/CFO | 05/07/2013 | 01/10/2015 | |
| Contatto Relazioni con gli Investitori | 05/07/2013 | - | |
| Treasurer | 05/07/2013 | - |
Storia della carriera di Christopher Missling
Precedenti posizioni note di Christopher Missling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - | - |
| IMMUNOGEN, INC. | Direttore Finanziario/CFO | - | - |
Brimberg & Co.
 Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Corporate Officer/Principal | - | - |
| CURIS, INC. | Direttore Finanziario/CFO | - | - |
Formazione di Christopher Missling
| Ludwig-Maximilians-Universität München | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
| WHU-Otto Beisheim School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
| Germania | 3 |
Posizioni
| Director of Finance/CFO | 3 |
| Masters Business Admin | 2 |
| Corporate Officer/Principal | 2 |
Settori
| Health Technology | 4 |
| Consumer Services | 4 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CURIS, INC. | Health Technology |
| ANAVEX LIFE SCIENCES CORP. | Health Technology |
| Aziende private | 3 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Brimberg & Co.
Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Finance |
| Aventis, Inc. |
- Borsa valori
- Insiders
- Christopher Missling
- Esperienza
